AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14684673 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 14684673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 14684673 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 0
Study 11455143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (topical corticosteroid + barrier cream)
Number of subjects: 14
Study 11455143 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid
Number of subjects: 14
Study 11455143 — intervention group
Group type: COMPARATOR
Intervention: Barrier cream
Number of subjects: 14
Study 11455143 — intervention group
Group type: COMPARATOR
Intervention: No treatment (fourth patch)
Number of subjects: 14
Study 10050213 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization
Number of subjects: 387
Study 10050213 — intervention group
Group type: COMPARATOR
Intervention: Microsurgery or radiosurgery
Number of subjects: 387
Study 10050213 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 387
Study 10050213 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic superselective microcatheterization
Number of subjects: 387
Study 8014444 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil
Number of subjects: 0
Study 8014444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2513047 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (active treatment)
Number of subjects: 19000
Study 2513047 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19000
Study 785427 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorbed surface-antigen influenza vaccine
Number of subjects: 0
Study 30859320 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise protocol inducing DOMS (trunk flexion-extension in a prone position with loads corresponding to participant's trunk weight plus 10% of their trunk extension maximal voluntary contraction)
Number of subjects: 24
Study 30859320 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise protocol inducing DOMS
Number of subjects: 24
Study 27871927 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed magnetic stimulation (16 sessions over 2 months)
Number of subjects: 120
Study 27871927 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed magnetic stimulation (32 sessions total)
Number of subjects: 120
Study 27871927 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed magnetic stimulation (16 sessions)
Number of subjects: 120
Study 27871927 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 120
Study 27871927 — intervention group
Group type: COMPARATOR
Intervention: No active pulsed magnetic stimulation (control)
Number of subjects: 120
Study 25900027 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 40
Study 24021959 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS) 6 mg/24h
Number of subjects: 322
Study 24021959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 322
Study 21240530 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (undercutting laminectomy augmented with transpedicular-instrumented fusion)
Number of subjects: 94
Study 21240530 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 94
Study 18430318 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 85
Study 18430318 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 85
Study 18430318 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of treatment
Number of subjects: 85
Study 16878682 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic phototherapy (Biolight)
Number of subjects: 20
Study 16878682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: Patlak graphical analysis
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified kinetic method (SKM)
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV (normalised for lean body mass and with a correction for plasma glucose)
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV-based net influx constant
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lesion evaluation (TLE)
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: SUV (normalised for body surface area)
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: 6P model
Number of subjects: 20
Study 12640556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour to non-tumour ratio (TNT)
Number of subjects: 20
Study 11524464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylan extended-release phenytoin sodium capsules with food
Number of subjects: 24
Study 11524464 — intervention group
Group type: COMPARATOR
Intervention: Dilantin Kapseals with food
Number of subjects: 24
Study 9159703 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive follow-up laboratory and radiologic testing (except for nonseminomatous germ cell tumors)
Number of subjects: 0
Study 9159703 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited panel of blood tests and radiographic studies
Number of subjects: 0
Study 9159703 — intervention group
Group type: EXPERIMENTAL
Intervention: More restrictive policy of follow-up testing
Number of subjects: 0
Study 8320940 — intervention group
Group type: EXPERIMENTAL
Intervention: AN 69 membrane
Number of subjects: 54
Study 8320940 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan
Number of subjects: 54
Study 3098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 50 micrograms
Number of subjects: 8
Study 3098255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 100 micrograms
Number of subjects: 8
Study 3098255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31446180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype analysis for NUDT15, FTO, and TPMT variants; patients heterozygous for any variant received 50 mg azathioprine equivalents, homozygous patients received alternative drugs; those without variants and non-genotyping group received 50 mg azathioprine equivalents with dose escalation.
Number of subjects: 164
Study 31446180 — intervention group
Group type: COMPARATOR
Intervention: Non-genotyping group (no genotype analysis); received 50 mg azathioprine equivalents followed by dose escalation.
Number of subjects: 164
Study 31446180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype analysis (pretreatment)
Number of subjects: 164
Study 31446180 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum dose of thiopurines
Number of subjects: 164
Study 31446180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype analysis
Number of subjects: 164
Study 27232208 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy
Number of subjects: 156
Study 27232208 — intervention group
Group type: COMPARATOR
Intervention: Therapy as usual
Number of subjects: 156
Study 28673741 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-T
Number of subjects: 141
Study 28673741 — intervention group
Group type: COMPARATOR
Intervention: NST-T
Number of subjects: 141
Study 26625869 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP ETT (n=20)
Number of subjects: 30
Study 26625869 — intervention group
Group type: COMPARATOR
Intervention: Standard ETT (n=10)
Number of subjects: 30
Study 24007717 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (AT, n=17)
Number of subjects: 87
Study 24007717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT, n=34)
Number of subjects: 87
Study 24007717 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Therapy plus Atorvastatin (HT+AT, n=36)
Number of subjects: 87
Study 24007717 — intervention group
Group type: COMPARATOR
Intervention: Hormone Therapy (HT)
Number of subjects: 87
Study 24007717 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (AT)
Number of subjects: 87
Study 20100811 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg alagebrium twice daily
Number of subjects: 102
Study 20100811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18166796 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD (thalidomide, doxorubicin, dexamethasone)
Number of subjects: 0
Study 18166796 — intervention group
Group type: COMPARATOR
Intervention: VAD (vincristine, adriamycin, dexamethasone)
Number of subjects: 0
Study 16386450 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep abdominal muscle contractions (TrA and IO)
Number of subjects: 20
Study 16386450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) strength assessment
Number of subjects: 20
Study 16386450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to voluntarily contract deep abdominal muscles
Number of subjects: 20
Study 16386450 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength of pelvic floor muscles (PFMs)
Number of subjects: 20
Study 15000272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 647
Study 15000272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study 11270018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 7.5%
Number of subjects: 40
Study 11270018 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 40
Study 9296424 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 45
Study 9296424 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (ISO)
Number of subjects: 45
Study 9296424 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 45
Study 8376696 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 49
Study 8376696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3536262 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy plus salmon calcitonin 100 MRC units daily for 3 weeks (Group II)
Number of subjects: 24
Study 3536262 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy alone (Group I)
Number of subjects: 24
Study 31952916 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cawthorne & Cooksey protocol (n = 40)
Number of subjects: 82
Study 31952916 — intervention group
Group type: COMPARATOR
Intervention: Multimodal Cawthorne & Cooksey protocol (n = 42)
Number of subjects: 82
Study 29032769 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 69
Study 29032769 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 69
Study 29032769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 27885290 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anaesthesia (SA)
Number of subjects: 120
Study 27885290 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 120
Study 24721024 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural sedation analgesia (SA) with ketamine 1 to 2 mg/kg intravenously
Number of subjects: 41
Study 24721024 — intervention group
Group type: COMPARATOR
Intervention: Suprascapular nerve block (SNB) under ultrasound guidance
Number of subjects: 41
Study 24721024 — intervention group
Group type: COMPARATOR
Intervention: Procedural sedation analgesia (SA)
Number of subjects: 41
Study 24721024 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SNB)
Number of subjects: 41
Study 22349708 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable shocks (US‐only group)
Number of subjects: 3
Study 22349708 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicitly unpaired presentations of a neutral shape and the shock (Unpaired group)
Number of subjects: 3
Study 22349708 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired shape‐shock presentations (Paired group)
Number of subjects: 3
Study 20450757 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-abortion counseling and education (PACE)
Number of subjects: 189
Study 20450757 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 189
Study 18028472 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (46‐50 Gy) and surgery
Number of subjects: 150
Study 18028472 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation and surgery
Number of subjects: 150
Study 11465654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 33
Study 11465654 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 33
Study 11465654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril and Losartan
Number of subjects: 33
Study 9629934 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration (FR) program
Number of subjects: 238
Study 9629934 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 238
Study 9629934 — intervention group
Group type: COMPARATOR
Intervention: Less intensive treatment programs
Number of subjects: 238
Study 8185007 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 11
Study 8185007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2896556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0
Study 2896556 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta 1-selective blocker)
Number of subjects: 0
Study 2896556 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (nonselective beta-blocker)
Number of subjects: 0
Study 31650217 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-MR enterography without bowel purgation
Number of subjects: 50
Study 31650217 — intervention group
Group type: COMPARATOR
Intervention: PET-MR enterography with bowel purgation
Number of subjects: 50
Study 31650217 — intervention group
Group type: EXPERIMENTAL
Intervention: MR morphological parameters (MRmorph)
Number of subjects: 50
Study 30289485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (25 mg DPV)
Number of subjects: 96
Study 30289485 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal ring
Number of subjects: 96
Study 28391798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diab (health video game)
Number of subjects: 179
Study 28391798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 179
Study 25615629 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefix 750 (750 μg/cm(3) granules)
Number of subjects: 24
Study 25615629 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefix 150 (150 μg/cm(3) granules)
Number of subjects: 24
Study 25615629 — intervention group
Group type: COMPARATOR
Intervention: Control (autogenous iliac crest bone graft, ICBG)
Number of subjects: 24
Study 25615629 — intervention group
Group type: COMPARATOR
Intervention: Control (ICBG)
Number of subjects: 24
Study 25615629 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefix 750
Number of subjects: 24
Study 25615629 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefix 150
Number of subjects: 24
Study 24199982 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional periodontal treatment (CPT) and homeopathic medicine (HM)
Number of subjects: 60
Study 24199982 — intervention group
Group type: COMPARATOR
Intervention: Conventional periodontal treatment (CPT)
Number of subjects: 60
Study 21606877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling collar from the start (CC)
Number of subjects: 7
Study 21606877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling collar replaced at 30‐min intervals (CC(replaced))
Number of subjects: 7
Study 21606877 — intervention group
Group type: COMPARATOR
Intervention: No collar (NC)
Number of subjects: 7
Study 21606877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling collar (CC)
Number of subjects: 7
Study 18342185 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium 60 mg QD
Number of subjects: 564
Study 18342185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 16540862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care without physical therapy or modalities
Number of subjects: 681
Study 16540862 — intervention group
Group type: COMPARATOR
Intervention: Medical care without physical therapy
Number of subjects: 681
Study 16540862 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care with physical therapy
Number of subjects: 681
Study 16540862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 681
Study 16540862 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic and physical therapy
Number of subjects: 681
Study 16540862 — intervention group
Group type: COMPARATOR
Intervention: Medical care only
Number of subjects: 681
Study 12653262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and low-dose prednisolone
Number of subjects: 23
Study 10634337 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programs
Number of subjects: 1356
Study 10634337 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1356
Study 9190976 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (150 U/kg body wt, sc three times a week for 12 weeks)
Number of subjects: 35
Study 9190976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9190976 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (responders)
Number of subjects: 35
Study 9190976 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO and Placebo
Number of subjects: 35
Study 1347205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.06 mg.kg-1
Number of subjects: 0
Study 1347205 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.2 mg.kg-1
Number of subjects: 0
Study 31767584 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation
Number of subjects: 40
Study 31767584 — intervention group
Group type: COMPARATOR
Intervention: No cardiopulmonary resuscitation
Number of subjects: 40
Study 29789925 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 gene rs28371725 CC and CT genotypes in PPE
Number of subjects: 208
Study 29789925 — intervention group
Group type: COMPARATOR
Intervention: CYP2D6 gene rs1065852 nonresponsive to labetalol
Number of subjects: 208
Study 26885316 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking black coffee three or more times per day
Number of subjects: 3497
Study 26885316 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking black coffee
Number of subjects: 3497
Study 26885316 — intervention group
Group type: COMPARATOR
Intervention: Mixing creamer and sugar into coffee
Number of subjects: 3497
Study 24460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate estimation of drinker type
Number of subjects: 1895
Study 24460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Underestimation of drinker type
Number of subjects: 1895
Study 24460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Overestimation of drinker type
Number of subjects: 1895
Study 24460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive alcohol expectancies, protective and risky drinking behaviors, descriptive peer norms
Number of subjects: 1895
Study 24460860 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective and risky drinking behaviors
Number of subjects: 1895
Study 23217093 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (up to 20 + 5 sessions)
Number of subjects: 180
Study 23217093 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (augmented by recommendation for counseling center and physician information)
Number of subjects: 180
Study 20571894 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 0
Study 20307440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedscapes + standard care
Number of subjects: 152
Study 20307440 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 152
Study 16394300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel
Number of subjects: 415
Study 16394300 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel plus cisplatin
Number of subjects: 415
Study 12651033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy
Number of subjects: 2201
Study 12651033 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2201
Study 10848537 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg po)
Number of subjects: 10
Study 10848537 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.3 mU.kg(‐1).min(‐1) iv)
Number of subjects: 10
Study 10848537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (40 mg)
Number of subjects: 10
Study 10848537 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (5 mg) or Nicorandil (40 mg) or Glibenclamide and Nicorandil
Number of subjects: 10
Study 10848537 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia
Number of subjects: 10
Study 8869800 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic or pre‐emptive therapy
Number of subjects: 0
Study 8869800 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric therapy for febrile episodes
Number of subjects: 0
Study 8869800 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 0
Study 8869800 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive therapy
Number of subjects: 0
Study 1323974 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta serine (12 x 10(6) U, nasal drops, three times daily for 4.3 days)
Number of subjects: 38
Study 1323974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nasal drops, three times daily for 4.3 days)
Number of subjects: 38